




Newsletter July 2014



Dear GAPP collaborators,

It is six months since we last wrote to you and we thought it was time for a brief update. We have had several developments in the GAPP project during the first part of 2014 and are looking forward to seeing things progress over the next few months.

- We have had several manuscripts published since we last wrote to you. The papers were entitled:-
- **“Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay.”** (Lordkipanidzé M, *et al. Blood* 2014; DOI 10.1182/blood-2013-08-520387)
- **“A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction.”** (Nisar SP, *et al. Thromb Haemost* 2014; DOI 10.1160/TH13-08-0672)
- **“A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in protease-activated receptor 1 in a patient with chronic bleeding.”** (Patel YM, *et al. J Thromb Haemost* 2014; DOI 10.1111/JTH.12539)
- **“Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders.”** (Dovlatova N, *et al. J Thromb Haemost* 2014; DOI 10.1111/JTH.12555)
- A review entitled:- **“What is the role of genetic testing in the investigation of patients with suspected platelet function disorders?”** (Daly ME, *et al. Br J Haematol* 2014; DOI 10.1111/BJH.12751)
- All publications have “on behalf of the GAPP collaborative” included in their authorship listing. We have several other manuscripts presently in preparation or under review and hope that these will be published soon.
- The genetic investigation of patients recruited into the GAPP study is progressing well and we are continuing to identify **potential disease causing genes** using **whole exome DNA sequencing**. We will feedback the results to you as and when we find them.
- Total GAPP recruitment has now reached 630 participants. As the study is open until the end of 2016 we have extended the study to 700 participants. In addition we have recently added Kent & Canterbury Hospital and Lincoln County Hospital as new approved centres onto the study and have already tested patients from these centres.
- Please direct all queries to **Dr Neil Morgan**, n.v.morgan@bham.ac.uk who is coordinating patient referrals and testing.

Finally we would like to thank you very much for your ongoing support of the project. Please remember to contact us if you have any questions. We wish you all a great summer and hope you get the chance for a holiday at some stage.

Best wishes

Neil Morgan

on behalf of the GAPP collaborative

Steve Watson, Chief Investigator - Principal Investigators: Dr Martina Daly (Sheffield), Dr Stuart Mundell (Bristol), Dr Andrew Mumford (Bristol) and Dr Paul Gissen (London)